phase 1_initiation
saveBayer AG — asundexian (Phase I Trial Initiation)
community read0 votes
Therapy area: Cardiovascular. Indication: Ischemic Stroke
Data sources
globaldata
Found something off?
same company · ±60 days · 6
- phase 1 2 completionavelumab: Bayer AG — avelumab (Phase I/II Trial Completion)Apr 30, 2026
- device adverse eventESSURE — Injury eventMar 31, 2026
- device adverse eventESSURE — Injury eventMar 31, 2026
- device adverse eventESSURE — Injury eventMar 31, 2026
- device adverse eventESSURE — Injury eventMar 31, 2026
- approvalNAPROXEN SODIUM: ALEVE (NAPROXEN SODIUM) — FDA approvalMar 10, 2026
comments(0)
5-min edit window · permanent after that